Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 83

Similar articles for PubMed (Select 23297635)

1.

[Activation of lymphocytes under the influence of an influenza vaccine combined with a low molecular weight germanium organic compound].

Liashenko VA, Akhmatova NK, Ambrosov IV, Matelo SK, Akhmatov ÉA, Sukhno AS, Khomenkov VG.

Zh Mikrobiol Epidemiol Immunobiol. 2012 Nov-Dec;(6):64-8. Russian.

PMID:
23297635
2.

[Activating effect of a germanium-organic compound on immunocompetent cells during intranasal immunization of mice with a live influenza vaccine].

Liashenko VA, Akhmatova NK, Ambrosov IV, Matelo SK, Markushin SG, Akhmatov ÉA, Sukhno AS, Khomenkov VG.

Zh Mikrobiol Epidemiol Immunobiol. 2013 May-Jun;(3):60-8. Russian.

PMID:
24000595
3.

[Influence of chitosan on immunophenotype and functional activity of murine mononuclear leukocytes after immunization with inactivated influenza vaccine].

Akhmatova NK, Egorova NB, Kurbatova EA, Semenova IB, Kuz'menko OM, Shcherbakov RV, Markushin SG, Gendon IuZ.

Zh Mikrobiol Epidemiol Immunobiol. 2008 Nov-Dec;(6):31-5. Russian.

PMID:
19186542
4.
5.

Two doses of parenterally administered split influenza virus vaccine elicited high serum IgG concentrations which effectively limited viral shedding upon challenge in mice.

Hovden AO, Cox RJ, Madhun A, Haaheim LR.

Scand J Immunol. 2005 Oct;62(4):342-52. Erratum in: Scand J Immunol. 2005 Oct;62(4):420.

PMID:
16253121
6.

Bacterium-like particles supplemented with inactivated influenza antigen induce cross-protective influenza-specific antibody responses through intranasal administration.

de Haan A, Haijema BJ, Voorn P, Meijerhof T, van Roosmalen ML, Leenhouts K.

Vaccine. 2012 Jul 6;30(32):4884-91. doi: 10.1016/j.vaccine.2012.04.032. Epub 2012 Apr 23.

PMID:
22537989
7.

Induction of cross-protective immunity against influenza A virus H5N1 by an intranasal vaccine with extracts of mushroom mycelia.

Ichinohe T, Ainai A, Nakamura T, Akiyama Y, Maeyama J, Odagiri T, Tashiro M, Takahashi H, Sawa H, Tamura S, Chiba J, Kurata T, Sata T, Hasegawa H.

J Med Virol. 2010 Jan;82(1):128-37. doi: 10.1002/jmv.21670.

PMID:
19950232
8.

Intranasal administration of a flagellin-adjuvanted inactivated influenza vaccine enhances mucosal immune responses to protect mice against lethal infection.

Hong SH, Byun YH, Nguyen CT, Kim SY, Seong BL, Park S, Woo GJ, Yoon Y, Koh JT, Fujihashi K, Rhee JH, Lee SE.

Vaccine. 2012 Jan 5;30(2):466-74. doi: 10.1016/j.vaccine.2011.10.058. Epub 2011 Oct 31.

PMID:
22051136
9.

[Chitosan as an adjuvant for parenteral inactivated influenza vaccines].

Gendon IuZ, Markushin SG, Krivtsov GG, Akopova II.

Vopr Virusol. 2008 Sep-Oct;53(5):14-9. Russian.

PMID:
19069787
10.

Immunogenicity, protective efficacy and mechanism of novel CCS adjuvanted influenza vaccine.

Even-Or O, Samira S, Rochlin E, Balasingam S, Mann AJ, Lambkin-Williams R, Spira J, Goldwaser I, Ellis R, Barenholz Y.

Vaccine. 2010 Sep 7;28(39):6527-41. doi: 10.1016/j.vaccine.2010.04.011. Epub 2010 Apr 21.

PMID:
20412874
11.

Efficacy, immunogenicity and stability of a novel intranasal nanoemulsion-adjuvanted influenza vaccine in a murine model.

Hamouda T, Chepurnov A, Mank N, Knowlton J, Chepurnova T, Myc A, Sutcliffe J, Baker JR.

Hum Vaccin. 2010 Jul;6(7):585-94.

12.

Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.

Prabakaran M, Velumani S, He F, Karuppannan AK, Geng GY, Yin LK, Kwang J.

Virology. 2008 Oct 25;380(2):412-20. doi: 10.1016/j.virol.2008.08.002. Epub 2008 Sep 10.

13.

Superior protection provided by a single dose of MF59-adjuvanted whole inactivated H5N1 influenza vaccine in type 1 diabetic mice.

Wu J, Wang F, Fang F, Zhang W, Chang H, Zheng L, Chen Z.

Arch Virol. 2011 Mar;156(3):387-95. doi: 10.1007/s00705-010-0860-4. Epub 2010 Nov 26.

PMID:
21110049
14.

The route of immunization with adenoviral vaccine influences the recruitment of cytotoxic T lymphocytes in the lung that provide potent protection from influenza A virus.

Suda T, Kawano M, Nogi Y, Ohno N, Akatsuka T, Matsui M.

Antiviral Res. 2011 Sep;91(3):252-8. doi: 10.1016/j.antiviral.2011.06.008. Epub 2011 Jun 21.

PMID:
21722671
16.

Relationship between structure and adjuvanticity of N,N,N-trimethyl chitosan (TMC) structural variants in a nasal influenza vaccine.

Hagenaars N, Verheul RJ, Mooren I, de Jong PH, Mastrobattista E, Glansbeek HL, Heldens JG, van den Bosch H, Hennink WE, Jiskoot W.

J Control Release. 2009 Dec 3;140(2):126-33. doi: 10.1016/j.jconrel.2009.08.018. Epub 2009 Aug 25.

PMID:
19712713
17.

Flow cytometric analysis of cellular changes in mice after intradermal inoculation with a liposome-iscom adjuvanted vaccine.

San Gil F, Turner B, Mullbacher A, Walker MJ, Djordjevic SP, Eamens GJ, Chin JC.

Scand J Immunol. 1998 Mar;47(3):243-53.

PMID:
9519863
18.

Protection against influenza virus infection by intranasal vaccine with surf clam microparticles (SMP) as an adjuvant.

Ichinohe T, Watanabe I, Tao E, Ito S, Kawaguchi A, Tamura S, Takahashi H, Sawa H, Moriyama M, Chiba J, Komase K, Suzuki Y, Kurata T, Sata T, Hasegawa H.

J Med Virol. 2006 Jul;78(7):954-63.

PMID:
16721854
19.

Immunological effects of the orally administered neuraminidase inhibitor oseltamivir in influenza virus-infected and uninfected mice.

Burger RA, Billingsley JL, Huffman JH, Bailey KW, Kim CU, Sidwell RW.

Immunopharmacology. 2000 Apr;47(1):45-52.

PMID:
10708809
20.

Effect of dietary high doses of vitamin E on lymphocyte subsets in young and old CBA mice.

Brohée D, Nève P.

Mech Ageing Dev. 1994 Oct 20;76(2-3):189-200.

PMID:
7533870
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk